Pharmaceuticals News

COPENHAGEN, Denmark, November 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on September 1, 2026, has now been completed,...

KØBENHAVN, Danmark, 2. november 2026 – Bavarian Nordic A/S (OMX: BAVA) meddeler, at aktietilbagekøbsprogrammet, der blev offentliggjort og iværksat den 1. september 2026, nu er afsluttet, da aktier...

Point d’étape sur les discussions avec les partenaires financiers Villepinte, le 2 novembre 2026, 8h30 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour...

Update on discussions with financial partners Villepinte, November 2, 2026, 8.30 A.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging,...

Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic...

GENFIT to Highlight Progress in ACLF and MASH Diagnostics at AASLD The Liver Meeting® 2026

GENFIT présentera ses avancées dans l’ACLF et dans le diagnosticde la MASH lors du congrès AASLD The Liver Meeting® 2026

COPENHAGEN, Denmark, November 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has been awarded a new multi-year contract by the UK Government through the UK Health Security Agency...

KØBENHAVN, Danmark, 2. november 2026 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået en ny flerårig kontrakt med den britiske regering gennem UK Health Security Agency...

— Follows US FDA new drug application submission in September 2026, marking important global regulatory progress — — Filings supported by positive SAFFRON global Phase III data demonstrating...